AstraZeneca PLC (LON:AZN)
London
· Delayed Price · Currency is GBP · Price in GBX 10,574
-146 (-1.36%)
Jun 2, 2025, 7:06 PM BST
AstraZeneca Revenue
AstraZeneca had revenue of $13.59B USD in the quarter ending March 31, 2025, with 7.17% growth. This brings the company's revenue in the last twelve months to $54.98B, up 15.48% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$54.98B
Revenue Growth
+15.48%
P/S Ratio
3.85
Revenue / Employee
$583.05K
Employees
94,300
Market Cap
163.97B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| GSK plc | 31.53B |
| Haleon | 11.23B |
| Smith & Nephew | 4.64B |
| ConvaTec Group | 1.83B |
| Hikma Pharmaceuticals | 2.50B |
| HUTCHMED (China) | 503.39M |
| Genus | 671.60M |
| Oxford Nanopore Technologies | 183.19M |
AstraZeneca News
- 8 hours ago - AstraZeneca says Enhertu, Perjeta combo cuts death risk in breast cancer - Seeking Alpha
- 17 hours ago - AstraZeneca CEO on breast cancer drug trial: This is the future of cancer treatment - CNBC
- 17 hours ago - How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma - Investor's Business Daily
- 17 hours ago - ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial - Benzinga
- 17 hours ago - ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 Phase 3 Trial - Benzinga
- 18 hours ago - Experimental AstraZeneca pill helps cut risk of breast cancer progression - CNBC
- 1 day ago - Notable healthcare headlines for the week: AstraZeneca, Eli Lilly, Bristol Myers in focus - Seeking Alpha
- 1 day ago - DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer - Benzinga